Born to Trouble

Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries

The Khazar region; How much Trouble for Iran?

Khazarprovide Iran with an excellent geopolitical position, while Iran's "antdomination policy" not only deprive it from these privileges but alsobring some serious security challenges for it. U.S. engagement in vasteconomic, military and political undertakings in this region is one of majorthreat for Iran's vital interests. I'm going to argue here that majordifficulty in the way of consisting ...

The Conundrum of Online Prescription Drug Promotion; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings confirm some of the early concerns, they also provide a perspective of implement...

The Earliest Stages of Delinquency

in the book. Dr. Edelston has conscientiously thought of delinquency from the administrator's point of view : The child is a delinquent when he has broken the law. Legally this cannot be until the age of eight years and logically enough Dr. Edelston does not give a case-history of a child younger than seven years old although he reports mothers as saying that their child has been a trouble sinc...

Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about th...